ASX Announcement Quarterly Activities Report & Appendix 4C § Successfully listed on the ASX following an $8m IPO, which fully funds the Phase 2 CERE-CALM trial and a preclinical blood-brain barrier opening program, and supports next-generation device development § Phase 2 CERE-CALM trial readied...